OTLK

Outlook Therapeutics, Inc. [OTLK] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

OTLK Stock Summary

Top 10 Correlated ETFs

OTLK

Top 10 Correlated Stocks

OTLK

In the News

OTLK Financial details

Company Rating
-
Market Cap
187.78M
Income
-51.5M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
24
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-1502903.19
Forward P/E
-
PEG
417994.95
P/S
-
P/B
-6449451.52
P/C
-
P/FCF
-2.25
Quick Ratio
0.5
Current Ratio
0.66
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.99
EPS next Y
-
EPS next Q
-
EPS this Y
-24.24%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
19.96%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-14%
-
-
-
-
SMA20
-21.56%
SMA50
-18.18%
SMA100
-70.36%
Inst Own
-
Inst Trans
-
ROA
-192%
ROE
-3930%
ROC
3.68%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.0-40.6
52W High
-96.1%
52W Low
-61%
RSI
34.22
Rel Volume
1.16
Avg Volume
648.3K
Volume
753.06K
Perf Week
-6.59%
Perf Month
-32.17%
Perf Quarter
-79.28%
Perf Half Y
-78.54%
-
-
-
-
Beta
0.192
-
-
Volatility
0.1%, 0.23%
Prev Close
-4.88%
Price
1.56
Change
-8.24%

Something similar

Top by Market Cap
LLY.SW
FXAIX
BRYN.DE
JPM
GOOGL
Top Correlated ETFs
GRI
TSLY
PSCE
BTF
TSL
Top Correlated Stocks
ANY
BLNK
GOVX
ANF
HCSG
Similar Market Cap
STOT
DXS6.DE
AMAR3.SA
PGUCX
VCB.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 648.3K
  • Market Capitalization 187.78M
  • Employee 24
  • CEO Mr. C. Russell Trenary III
  • Headquarters Iselin,NJ,US
  • IPO Date 2016-06-14
  • Website https://www.outlooktherapeutics.com

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.